Pharvaris (NASDAQ:PHVS - Get Free Report) shares saw an uptick in trading volume on Friday . 40,333 shares were traded during trading, an increase of 15% from the previous session's volume of 34,958 shares.The stock last traded at $18.58 and had previously closed at $18.54.
Analyst Upgrades and Downgrades
Separately, Oppenheimer upped their target price on Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a research report on Friday, September 6th.
View Our Latest Report on PHVS
Pharvaris Stock Performance
The firm has a market cap of $590.00 million, a price-to-earnings ratio of -6.62 and a beta of -3.17. The firm's 50 day moving average is $20.76 and its 200-day moving average is $19.36.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new stake in Pharvaris during the third quarter worth approximately $57,000. Barclays PLC bought a new stake in shares of Pharvaris during the 3rd quarter worth $106,000. Geode Capital Management LLC grew its stake in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock valued at $685,000 after buying an additional 5,753 shares during the last quarter. HighVista Strategies LLC raised its holdings in Pharvaris by 35.9% in the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock worth $422,000 after acquiring an additional 6,018 shares during the period. Finally, Sofinnova Investments Inc. lifted its position in Pharvaris by 2.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company's stock worth $11,309,000 after acquiring an additional 16,862 shares during the last quarter.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
